The Trifecta Effect poster presentation by Sandy Castillo at the 2014 American Association for Cancer Research, AACR, Survivor Scientist Program, SSP
TheTrifectaEffectSMC – Poster Image reflecting what one advocate can do in one year
The Trifecta Effect – Hand out outlining breast cancer focused educational scholarships

Scientifically-trained Patient Advocates – also known as Trifectas – can change the face of cancer.  Trifectas educate, train, mentor, and mobilize researchers and legislators by taking an active seat at the table where patient advocates voice their views with those at the grass tops.  Bridging the gap for patient-driven medicine and safe quality outcomes hinges on enabling and mobilizing more Trifectas.

A top legislative priority of The National Breast Cancer Coalition is to “Ensure the Participation of Educated Patient Advocates in all Levels of Health Care Decision Making” and as such NBCC continues to work to ensure that resources such as Trifectas have a seat at that table with the potential to influence all levels of health care decision making.


The Ecology of Breast Cancer The Promise of Prevention and Hope for Healing by Ted Schettler, MD, MPH
“Dr Schettler makes a convincing case that we must look more broadly at breast cancer to understand it. If we are able to understand the individual biology and lifestyle along with the world the individual inhabits,we will surely have a better chance not only of helping people live once they’ve been diagnosed, but keeping them from going through the devastation of getting cancer in the first place. I hope we listen carefully to what The Ecology of Breast Cancer tells us and explore the area of the unknown that it identifies.” -Susan Braun, Board of Directors, Commonweal; breast cancer advocate


KomenAISBreastCancerSymposium2013-FinalReportDocument for distribution
November 15, 2013, Susan G. Komen Advocates in Science @ ASCO Breast Cancer Symposium Class 2013 Final Reports, including the team report on Immunotherapy by Sandy Castillo, Sandy Finestone and Janet Piper.

This report was prepared by Komen Advocates in Science members as a class assignment following attendance at the 2013 Breast Cancer Symposium. The purpose of this report is to inform Susan G. Komen Affiliates and the breast cancer community about the proceedings of the Symposium. Please note this material has been reviewed by
Komen educational and scientific staff but has not been medically reviewed for accuracy.


Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis
In the United States, approximately 14 million people have had cancer and more than 1.6 million new cases are diagnosed each year. By 2022, it is projected that there will be 18 million cancer survivors and, by 2030, cancer incidence is expected to rise to 2.3 million new diagnoses per year. However, more than a decade after the IOM first studied the quality of cancer care, the barriers to achieving excellent care for all cancer patients remain daunting. Therefore, the IOM convened a committee of experts to examine the quality of cancer care in the United States and formulate recommendations for improvement. Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis presents the committee’s findings and recommendations.

The committee concluded that the cancer care delivery system is in crisis due to a growing demand for cancer care, increasing complexity of treatment, a shrinking workforce, and rising costs. Changes across the board are urgently needed to improve the quality of cancer care. All stakeholders – including cancer care teams, patients and their families, researchers, quality metrics developers, and payers, as well as HHS, other federal agencies, and industries – must reevaluate their current roles and responsibilities in cancer care and work together to develop a higher quality cancer care delivery system. Working toward the recommendations outlined in this report, the cancer care community can improve the quality of life and outcomes for people facing a cancer diagnosis.


The CALOR Trial Advocate Report, SABCS 2012 by Sandy Castillo
Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer, The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer) Advocate Report distributed through Alamo Breast Cancer Foundation with a grant from AVON.  The report bridges the science of breast cancer with society for ease of understanding.

Aebi S, Gelber S, Lang I, et al. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial. Oral presentation at the 35th annual San Antonio Breast Cancer Symposium; December 4-8, 2012. San Antonio, TX. Abstract S3-2.


Leave A Reply